{"id":798409,"date":"2025-01-07T08:09:37","date_gmt":"2025-01-07T13:09:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/"},"modified":"2025-01-07T08:09:37","modified_gmt":"2025-01-07T13:09:37","slug":"md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/","title":{"rendered":"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay"},"content":{"rendered":"
\n

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) — The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc<\/u><\/a>.<\/u><\/a> today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad\u2019s molecular residual disease (MRD) assay.<\/p>\n

This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad\u2019s Precise MRD.<\/p>\n

\u201cWe look forward to working with MD Anderson to evaluate Precise MRD\u2019s utility in cancer care,\u201d said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. \u201cOur collaborative studies will explore how our ultrasensitive Precise MRD test can enhance treatment strategies for providers and improve patient outcomes. We are optimistic that our MRD test\u2019s ability to quantitatively detect tumor-derived DNA at very low levels \u2014 far lower than is possible with first-generation MRD tests \u2014 will open new opportunities for therapy-response and recurrence monitoring.\u201d<\/p>\n

Under the terms of the agreement, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies to investigate the test\u2019s utility in breast, gastrointestinal, genitourinary, and gynecological cancers. The goal of these studies is to generate evidence that supports national guideline inclusion and healthcare provider adoption. MD Anderson investigators will lead patient enrollment, sample collection, clinical data analysis and manuscript writing. Myriad will provide funding, MRD testing and scientific research support as well as potential milestone and royalty payments under the collaboration.<\/p>\n

\u201cThis strategic alliance brings together cutting-edge technology and expertise from Myriad with disease-focused expertise and clinical trials excellence from MD Anderson,\u201d said Christopher Flowers, M.D.<\/u><\/a>, division head of Cancer Medicine at MD Anderson. \u201cWe aim to explore numerous applications for MRD testing, including monitoring patients for relapse after treatment, identifying high-risk patients in need of clinical trials, and potentially intervention approaches.\u201d<\/p>\n

The alliance expands upon existing collaborations between MD Anderson researchers and Myriad, including ongoing studies in breast cancer and renal cell carcinoma.<\/p>\n

\n About Myriad Genetics<\/strong>
\n
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit Myriad.com<\/u><\/a>.<\/p>\n

\n
\n About MD Anderson<\/u>
\n <\/strong>
\n
\n
\n The University of Texas MD Anderson Cancer Cente<\/u>
\n r<\/u>
\n <\/a> in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution\u2019s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation\u2019s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD\u00a0Anderson is No. 1 for cancer in U.S. News & World Report\u2019s \u201cBest Hospitals\u201d rankings and has been named one of the nation\u2019s top two hospitals for cancer since the rankings began in 1990. MD\u00a0Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).<\/p>\n

\n Safe Harbor Statement<\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including that Myriad will work with MD Anderson to evaluate Precise MRD\u2019s utility in cancer care, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies to investigate the test\u2019s utility in breast, gastrointestinal, genitourinary, and gynecological cancers, the collaborative studies will explore how the Precise MRD test can enhance treatment strategies for providers and improve patient outcomes, and Myriad\u2019s belief that its MRD test\u2019s ability to quantitatively detect tumor-derived DNA at very low levels will open new opportunities for therapy-response and recurrence monitoring. These \u201cforward-looking statements\u201d are management\u2019s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company\u2019s filings with the U.S. Securities and Exchange Commission, including the company\u2019s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company\u2019s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.<\/p>\n

\n Investor Contact\u00a0<\/strong>
\n
Matt Scalo\u00a0
(801) 584-3532\u00a0
IR@myriad.com<\/u><\/a>\u00a0<\/p>\n

\n Media Contact\u00a0<\/strong>
\n
Glenn Farrell\u00a0
(385) 318-3718\u00a0
PR@myriad.com<\/u><\/a>\u00a0\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) — The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad\u2019s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad\u2019s Precise MRD. \u201cWe look forward to working with MD Anderson to evaluate Precise MRD\u2019s utility in cancer care,\u201d said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. \u201cOur collaborative studies will explore how our ultrasensitive Precise MRD test … <\/p>\n

Continue reading “MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798409","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) — The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad\u2019s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad\u2019s Precise MRD. \u201cWe look forward to working with MD Anderson to evaluate Precise MRD\u2019s utility in cancer care,\u201d said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. \u201cOur collaborative studies will explore how our ultrasensitive Precise MRD test … Continue reading "MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T13:09:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay\",\"datePublished\":\"2025-01-07T13:09:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/\"},\"wordCount\":807,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/\",\"name\":\"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=\",\"datePublished\":\"2025-01-07T13:09:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/","og_locale":"en_US","og_type":"article","og_title":"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay - Market Newsdesk","og_description":"HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) — The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad\u2019s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad\u2019s Precise MRD. \u201cWe look forward to working with MD Anderson to evaluate Precise MRD\u2019s utility in cancer care,\u201d said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. \u201cOur collaborative studies will explore how our ultrasensitive Precise MRD test … Continue reading \"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-07T13:09:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay","datePublished":"2025-01-07T13:09:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/"},"wordCount":807,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/","name":"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=","datePublished":"2025-01-07T13:09:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzM5MCM2NjgxMTk0IzIwMDc4ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-myriads-molecular-residual-disease-assay\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad\u2019s molecular residual disease assay"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798409"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798409\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}